Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4570565
Max Phase: Preclinical
Molecular Formula: C73H107N17O13
Molecular Weight: 1430.77
Molecule Type: Unknown
Associated Items:
ID: ALA4570565
Max Phase: Preclinical
Molecular Formula: C73H107N17O13
Molecular Weight: 1430.77
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CC(C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(=N)N)N(C)C(=O)[C@H](N)CCCCN)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)O)C(C)C
Standard InChI: InChI=1S/C73H107N17O13/c1-43(2)61(69(99)87-57(39-46-26-30-49(91)31-27-46)65(95)85-59(41-48-42-81-53-22-10-9-20-51(48)53)66(96)82-54(23-12-15-35-75)63(93)83-55(72(102)103)24-13-16-36-76)89-70(100)62(44(3)4)88-67(97)58(40-47-28-32-50(92)33-29-47)84-64(94)56(38-45-18-7-6-8-19-45)86-68(98)60(25-17-37-80-73(78)79)90(5)71(101)52(77)21-11-14-34-74/h6-10,18-20,22,26-33,42-44,52,54-62,81,91-92H,11-17,21,23-25,34-41,74-77H2,1-5H3,(H,82,96)(H,83,93)(H,84,94)(H,85,95)(H,86,98)(H,87,99)(H,88,97)(H,89,100)(H,102,103)(H4,78,79,80)/t52-,54+,55-,56+,57+,58+,59+,60+,61+,62+/m1/s1
Standard InChI Key: HNEDBWDPIJSNPC-VRMFXZQISA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1430.77 | Molecular Weight (Monoisotopic): 1429.8234 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Denèfle T, Pramil E, Gómez-Morales L, Levasseur MD, Lardé E, Newton C, Herry K, Herbi L, Lamotte Y, Odile E, Ancellin N, Grondin P, Martinez-Torres AC, Viviani F, Merle-Beral H, Lequin O, Susin SA, Karoyan P.. (2019) Homotrimerization Approach in the Design of Thrombospondin-1 Mimetic Peptides with Improved Potency in Triggering Regulated Cell Death of Cancer Cells., 62 (17): [PMID:31403795] [10.1021/acs.jmedchem.9b00024] |
Source(1):